News
JAZZ
108.32
-1.23%
-1.35
Jazz Pharmaceuticals to Present Data Across Growing Oncology Pipeline and Portfolio at ASCO 2024
Barchart · 17h ago
3 No-Brainer Stocks to Buy With $300 Right Now
A modest amount of money can go a long way on Wall Street. With $300, you can buy three stocks with no-brainer catalysts right now. Bank of America and Jazz Pharmaceuticals are good buys for long-term investors with $300. The two companies are time-tested businesses with well-defined catalysts.
The Motley Fool · 23h ago
Jazz Pharmaceuticals (JAZZ) Gets a Buy from Barclays
TipRanks · 1d ago
Weekly Report: what happened at JAZZ last week (0415-0419)?
Weekly Report · 2d ago
JAZZ PHARMACEUTICALS PLC <JAZZ.O>: NEEDHAM RAISES TARGET PRICE TO $222 FROM $220
Reuters · 5d ago
CORRECTED-U.S. RESEARCH ROUNDUP-Blackstone, Ellington Financial, Netflix
Blackstone, Ellington Financial, Netflix revise their ratings and price targets on several U.S. Companies. Deutsche Bank raises Abbvie Inc target price to $175 from $170, and cuts it to $140 from $145. Blackstone, ellington financial and Netflix also revise their targets on Friday.
Reuters · 6d ago
Jazz Pharmaceuticals: Cheap But Complicated
Seeking Alpha · 6d ago
JAZZ PHARMACEUTICALS TO REPORT 2024 FIRST QUARTER FINANCIAL RESULTS ON MAY 1, 2024
Reuters · 04/17 20:15
Eli Lilly obesity therapy succeeds in late-stage trials for sleep disorder
Seeking Alpha · 04/17 11:04
Jazz Pharmaceuticals is Now Oversold (JAZZ)
NASDAQ · 04/16 20:22
Weekly Report: what happened at JAZZ last week (0408-0412)?
Weekly Report · 04/15 09:03
Jazz Pharmaceuticals: Targeting The Low-Hanging Fruit In Oncology Might Pay Off
Jazz Pharmaceuticals is targeting low-hanging fruit in oncology with its drug Zanidatamab. The drug has the potential to become a blockbuster drug with up to $2 billion/year in net sales. The company's most successful commercial products include Xywav, Epidiolex, and Rylaze. Jazz is rated a "Buy" due to its current financial health and projected growth for 2024 and 2025.
Seeking Alpha · 04/15 08:31
Alkermes' (ALKS) ALKS 2680 Betters Wakefulness in Phase Ib Study
NASDAQ · 04/11 14:15
Breaking Down Jazz Pharmaceuticals: 15 Analysts Share Their Views
15 analysts have published ratings on Jazz Pharmaceuticals (NASDAQ:JAZZ) in the last three months. The average price target is $196.6, with a 12-month price target of $235.00. The company is an Ireland-domiciled biopharmaceutical firm focused on sleeping disorders and oncology.
Benzinga · 04/10 14:01
Jazz Pharmaceuticals Price Target Maintained With a $180.00/Share by Cantor Fitzgerald
Dow Jones · 04/10 13:48
Cantor Fitzgerald Reiterates Overweight on Jazz Pharmaceuticals, Maintains $180 Price Target
Benzinga · 04/10 13:37
JAZZ PHARMACEUTICALS TO SHOWCASE EXPANSIVE NEUROSCIENCE PORTFOLIO AT AMERICAN ACADEMY OF NEUROLOGY ANNUAL MEETING
Reuters · 04/10 11:45
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bluebird Bio (BLUE), Sarepta Therapeutics (SRPT) and Jazz Pharmaceuticals (JAZZ)
Bluebird Bio, Sarepta Therapeutics and Jazz Pharmaceuticals have received a lot of coverage today. Bluebird Bio has a Hold rating from RBC Capital, while Sarepta Therapeutic has a Buy rating from Citi. The Healthcare sector has been the subject of a number of analyst reports.
TipRanks · 04/09 02:00
Weekly Report: what happened at JAZZ last week (0401-0405)?
Weekly Report · 04/08 09:03
Pharma Stock Roundup: AZN Voydeya Gets FDA Nod, MRK KRAS Inhibitor Enters Phase III
NASDAQ · 04/05 12:07
More
Webull provides a variety of real-time JAZZ stock news. You can receive the latest news about Jazz Pharmaceuticals Plc through multiple platforms. This information may help you make smarter investment decisions.
About JAZZ
Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company’s lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD).